Navigation Links
Baxa Corporation Signs Exclusive Distribution Agreement With Leading Pharmaceutical Corporation in People's Republic of China
Date:10/19/2009

ENGLEWOOD, Colo., Oct. 19 /PRNewswire/ -- Baxa Corporation, a US-based medical device company in Englewood, Colorado, has signed an exclusive four-year distribution agreement with SINOPHARM, a China National Pharmaceutical Foreign Trade Corporation, to promote sales of its products in China. While the agreement covers all Baxa products, the ExactaMix(TM) 2400 Automated Compounder and the Repeater(TM) Pharmacy Pump have been recognized as ones that will increase efficiency for the hospitals targeted by Baxa and SINOPHARM in the People's Republic of China (PRC). Due to their existing practice of manual preparation, the companies expect that more than 250 hospitals could benefit from the Baxa pharmacy automation equipment.

The partners anticipate that Baxa Corporation's expertise in automation could greatly improve the existing processes in Chinese hospitals - making their pharmacy operations more accurate, safe and efficient. "Baxa products are used all across the world every day by thousands of pharmacies. By entering the Chinese market, patients there will access the same outstanding quality that Baxa products have provided for 35 years in other parts of the world," states Phil Walsh, Baxa Director of International Sales.

"In China, the curtain has just been raised on the automation and digitization of the hospital pharmacy. Baxa products serve as an integral part for pharmacy automation," states Li Hai Bo, Medical Equipment Manager, SINOPHARM. "Parenteral nutrition is widely used in China," he continues, "however SINOPHARM believes that the current practice of manual preparation is inadequate and may not meet the varied needs of individual patients."

A key component of this partnership is the recent announcement of the China State Council to allocate 850 billion Yuan ($123 billion USD) to reform its medical and healthcare system. Technological advancement was cited as being vital to the plan's success in improving the quality of medical services to the country's 1.3 billion people.

Baxa Corporation was founded in 1975 by Brian Baldwin and Ronald Baxa. Through more than three decades of rapid growth and change in the healthcare industry, Baxa Corporation has become a leading global supplier of solutions for handling, measuring and administering fluid medications. In addition to its global headquarters in Englewood, CO, Baxa has subsidiaries and sales offices in Florida, Canada and the United Kingdom; direct representation within Europe and distribution partners worldwide.

About Baxa Corporation

Baxa, a customer-focused medical device company, provides innovative, solution-based technologies for medication handling and delivery. Its systems and devices promote the safe and efficient preparation, handling, packaging, and administration of medications. Key products include the PadLock® Set Saver, Rapid-Fill(TM) Automated Syringe Fillers, ExactaMed® Oral Dispensers, MicroFuse® Syringe Infusers, Repeater(TM) Pharmacy Pumps, the DoseEdge(TM) Dose Management System and ExactaMix(TM) Multi-Source Automated Compounders; used worldwide in hospitals and healthcare facilities. Its subsidiary FHT, Inc. produces the IntelliFill i.v. ® automation. Further information is available at www.baxa.com.

About SinoPHARM

Established in 1981, China National Pharmaceutical Foreign Trade Corporation (SINOPHARM Foreign Trade) is a wholly owned subsidiary of China National Pharmaceutical Group Corporation (SINOPHARM Group). SINOPHARM's core businesses are investment, import and export, and domestic distribution in pharmaceutical and relevant sections, including pharmaceutical R&D, consultation, bonded warehousing and other value-added services such as overseas pharmaceutical projects and domestic wholesale of pharmaceuticals, medical instruments and equipment. SINOPHARM keeps the country's medicine reserve and plays an important role in disaster and emergency relief and disease and plague prevention. For more information, visit http://www.sino-pharm.com.

    Contact:
    Marian Robinson, Vice President, Marketing
    Baxa Corporation:  800.567.2292 ext. 2157 or 303.617.2157
    Email:  marian.robinson@baxa.com

    Maggie Chamberlin Holben, APR
    Absolutely Public Relations: 303.984.9801 or 303.669.3558
    Email: maggie@absolutelypr.com

    Li Hai Bo, Medical Equipment Manager, Health Care Division
    SINOPHARM: +8610 82074502
    lihaibo@sinopharm.com

SOURCE Baxa Corporation


'/>"/>
SOURCE Baxa Corporation
Copyright©2009 PR Newswire.
All rights reserved

Related medicine technology :

1. Genaera Corporation Presents Interim Phase 1 Data for Obesity Compound Trodusquemine (MSI-1436) at IBC Conference
2. CEL-SCI Corporation Releases Letter to Shareholders
3. Alfacell Corporation to Present at UBS Global Life Sciences Conference
4. Baxa Corporation Extends Global Reach With New Distribution Agreements in Colombia and the Dominican Republic
5. Genaera Corporation Presents Preclinical Trodusquemine (MSI-1436) Data at the North American Association for the Study of Obesity Annual Meeting
6. Genaera Corporation Presents Phase 1 Data for Trodusquemine (MSI-1436) at the North American Association for the Study of Obesity Annual Meeting
7. The Quigley Corporation Reports Third Quarter Results, Increases Investment in Pharmaceutical R&D for Diabetic Neuropathy
8. Genaera Corporation Provides Highlights of Positive Phase 1 Trodusquemine (MSI-1436) Data from the North American Association for the Study of Obesity Annual Meeting
9. Crystal Research Associates, LLC Issues Executive Informational Overview(R) (EIO(R)) on CEL-SCI Corporation
10. Immunosyn Corporation Releases SF-1019 Study Results
11. AmpliMed Corporation Announces Promising 1-year Survival Data from Phase I/II Study of Amplimexon(R) in Metastatic Malignant Melanoma
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/20/2017)... -- AbbVie (NYSE: ABBV), a global biopharmaceutical company, today ... C virus (HCV) infected patients with genotype 1, ... (Child-Pugh A) achieved sustained virologic response at 12 ... pan-genotypic regimen of glecaprevir/pibrentasvir (G/P). These high SVR ... of G/P treatment without ribavirin. Patients with specific ...
(Date:4/20/2017)... , April 20, 2017 NeuroVive ... ("NeuroVive") today announced positive preclinical results demonstrating ... compound for non-alcoholic steatohepatitis (NASH), in an ... NV556 has previously shown similar ... model. Today, NeuroVive,s scientists present novel data ...
(Date:4/19/2017)... , April 19, 2017 Cardiology devices segment is ... period The Cardiology Devices segment is likely to ... 15 Mn in 2018 over 2017. By the end of ... valuation close to US$ 700 Mn, expanding at a CAGR ... dominated the Asia Pacific reprocessed medical ...
Breaking Medicine Technology:
(Date:4/26/2017)... (PRWEB) , ... April 26, 2017 , ... ... and clinical outcomes, today released the podcast, “Make Plans for MACRA,” ... value-based payment into the physician's office and how physicians and other clinicians are ...
(Date:4/26/2017)... ... April 26, 2017 , ... Elisabete Miranda, president ... honored by Enterprising Women magazine as one of its 2017 Enterprising Women of ... owners. Winners have demonstrated that they have fast-growth businesses, mentor or actively support ...
(Date:4/26/2017)... JOHYNSTON, Iowa (PRWEB) , ... April 26, 2017 ... ... agriculture? DuPont Pioneer today launched a unique website ( CRISPRCas.pioneer.com ) that demonstrates ... plants and help farmers produce more and better food, with fewer resources. It ...
(Date:4/25/2017)... San Jose, CA (PRWEB) , ... April 25, ... ... in cross-screen access, support, and collaboration, announces Mirroring360 Pro . This new ... providing a comprehensive collaboration experience for education and business. , Mirroring360 Pro enables ...
(Date:4/25/2017)... ... April 25, 2017 , ... A recent report from the ... for the 2015-16 school year across Wisconsin’s public schools, charter schools, and private ... patterns in student test score performance, the report’s limited analyses fail to provide ...
Breaking Medicine News(10 mins):